About Us

Delex Pharma International, Inc. (DPI) is the 3rd largest National Pharma Company in the Hospital Channel (based on iQVIA MAT Dec 2020) and an ISO 9001:2015-certified Filipino-owned pharma and medical device local company with Top-notch Global Partners. 

The company was incorporated and registered with the Securities & Exchange Commission (SEC) on July 13, 2009. It was established primarily to engage in trading goods such as medical supplies, equipment, pharmaceutical products, and food supplements on a wholesale & retail basis. Moreover, Delex was established to market the hospital & critical care range of products with a special focus on the intensive care setting, including the Intensive Care Units, Emergency Rooms, and Operating Theaters.

DPI gained reputable and world-class partners such as Philips (LUMIFY, handheld and Cardio ultrasound), Verathon (Glidescope) is a global leader in medical devices, delivering innovative and specialized medical solutions in airway management and Sandoz [Fentanyl Patch (FENTALEX)]. Among these renowned multinational companies is Kemex Laboratories of Argentina, carrying various quality oncology products.

Meanwhile, Delex made history as the pioneer in introducing Hypertonic Sodium Lactate (TOTILAC),  Ibuprofen IV (INTRAFEN), and Labetalol Hydrochloride (BETALEX) to the Philippine market. Delex Pharma is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital, Inc. Both entities are operating in the Philippines. DLX Holdings, Inc. is the organization’s immediate parent company.

Currently, the company provides the following solutions to target clients:

• Sales and Marketing
• Support for product registration and compliance
• Sales Order Processing 
• Invoicing & Collection
• Warehousing, Delivery, and Transportation
• Credit and Risk Management
• 24/7 Online Retail Pharmacy

Delex expanded its business by acquiring JMN Brothers Pharma Limited, Inc., and MD Pharma in 2022 as its subsidiaries, reinforcing its position in the OTC drugs and women’s health market. In 2023, it further diversified by introducing an oncology division as a new business line. Meanwhile, DPI strives to enhance community access to quality and affordable medicines 24/7. On October 18, 2021, it launched its drugstore channel---the Delex Pharmacy in Brgy. Sauyo, Quezon City, with subsequent branches in Santolan, Pasig City, and Kalibo, Aklan. Furthermore, the company is renowned as the “home of ICU Forum Programs”, as a PRC CPE provider offering free Continuing Medical Education (CME) to Healthcare Professionals (MED-2018-298; NRS-2018-269; PHA-2018-153) with a focus on the latest advancements in managing critically ill patients in the Intensive Care Settings.

Delex Pharma International, Inc. provides its customers and stakeholders with quality and cost-effective products and services in the hospital critical care area by:
• Committing to continuously enhance customer satisfaction
• Ensuring the effectiveness and efficiency of its processes
• Establishing and reviewing its quality objectives
• Providing adequate resources to implement the Quality Management System
• Adhering to statutory and regulatory requirements
 

To establish a premier Filipino-owned and managed pharmaceutical company providing quality critical care medicines and medical devices for critically ill Filipino patients.

We believe that each Filipino has the right access to comprehensive and safe treatment in ICU settings with quality and affordable critical care products. When every Filipino receives the proper care they deserve, it enables them to enjoy the gift of life.

As we envision building a sustainable nation, we established a company that provides decent job opportunities to Filipinos. With this, Delex Pharma contributes to increasing the employment rate in the country.

At Delex Pharma, we are responsible and accountable for the safety and satisfaction of our clients, partners, community, and people while providing our service. We adhere to the standards set forth by government entities in performing our work.

TO OUR PEOPLE: Become a great workplace, where people are inspired and motivated to be at their utmost best.

TO OUR MARKET: Bring to the Philippines a portfolio of quality, cost-effective, and much-needed vital brand medicines and medical devices for the hospital market.

TO OUR PARTNERS: Nurture a winning network of customers and suppliers towards a mutual and enduring culture of interdependence and cooperation.

TO OUR COMMUNITY: Be a responsible organization, making a difference by helping build and support a sustainable nation.

TO OUR STAKEHOLDERS: Deliver sustainable returns to shareowners while being mindful of overall responsibilities.

TO OUR PRODUCTIVITY: Become a highly effective, structure-efficient, and fast-growing organization.